IDH1 Inhibitor TQB3454 clinical trials
Its developmentBy Sino Biopharmaceutical, step by step5 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses IDH1 Inhibitor TQB3454 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IDH1 Inhibitor TQB3454 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test IDH1 Inhibitor TQB3454, phase 3 first.
- Dec 2026A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Studies
Open first, then newest update. How each study uses IDH1 Inhibitor TQB3454 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid TumorsNot yet recruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07738679Written as TQB3454 tablets
- A Study of TQB3454 Tablets in Patients With Blood TumorsRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06218771Written as TQB3454 Tablets
- A Clinical Trial of TQB3454 Tablets in Healthy Adult SubjectsNot yet recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06139367Written as TQB3454 tablets
- A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.Active, not recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05987358Written as TQB3454 tablets
- A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 TabletsStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04481607Written as TQB3454